collected at 184, 187, 188, 189, 190, 192 , and 195 min. Glyburide was then initiated and increased daily, while insulin was steadily withdrawn as tolerated to maintain euglycemia using a modified published protocol used for those with mutations affecting the ATP-sensitive potassium channel (2) .
Subjects were discharged on glyburide monotherapy with supplemental insulin only if required. Additional oral agents were subsequently added if needed to achieve complete insulin independence. Repeated-measures ANOVA was used to identify differences in metabolic variables between treatment conditions. When comparing MMT and AST before SU with those after a 5-day course of SU, there was no difference in the serum glucose, but C-peptide values were significantly higher in subjects following a course of SU (P , 0.05) ( Table 1) .
All four subjects remained on SU and off insulin therapy with good glycemic control at reevaluation at least 5 months after transition. One subject also required metformin, while two subjects required a combination of metformin and sitagliptin (Table 1) .
SU therapy has been used safely and effectively in other forms of diabetes for decades (e.g., type 2, KCNJ11, and HNF1A diabetes). SU therapy in type 2 diabetes has raised concerns in terms of hastening of b-cell failure (3); however, our data and other reports (4, 5) would suggest that insulin therapy may not be required for many years after relapse of diabetes in these patients. We, for the first time, demonstrate that insulin secretion in subjects with 6q24-TND improves in response to SU and provide further evidence that noninsulin-based therapies should be considered for the treatment of 6q24-TND.
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